Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Strong community engagement has been critical to support COVID-19 vaccine uptake in Australia and elsewhere. Community engagement builds trust, enables tailored information dissemination and shapes social norms. Engagement is particularly important in communities with greater vaccine hesitancy, lower health literacy and mistrust in authorities. Early in 2021, as a team of vaccine social scientists and clinicians, we developed a program to train and empower community, faith, industry and healthcare leaders to advocate for COVID-19 vaccines as “vaccine champions”. We partnered with the Victorian Department of Health to deliver 91 online Vaccine Champions sessions from March 2021 to June 2022. Over 80 people who received this training were supported by the Department of Health to become formal vaccine champions, independently delivering over 100 locally tailored information sessions. Our survey evaluation of 20 sessions delivered in 2022 found most participants (94%, 118/125) felt more confident to discuss safety and effectiveness of COVID-19 vaccines and find relevant information after attending a session. We also recorded >90% participant satisfaction with training content, format and presentation. Qualitative feedback from two group interviews highlighted the value of vaccine communication role plays and opportunities for discussion. In this brief report, we present an overview of the Vaccine Champions program, evaluation and next steps.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693559 | PMC |
| http://dx.doi.org/10.3390/vaccines10111893 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A randomized pilot study of HPV16 L2E7E6 fusion protein vaccination site post-treatment for HPV16+ cervical cancer.
Gynecol Oncol
August 2025
Department of Oncology, Johns Hopkins School of Medicine; Baltimore, MD, USA; Department of Gynecology/Obstetrics, Johns Hopkins School of Medicine; Baltimore, MD, USA; Department of Pathology, Johns Hopkins School of Medicine; Baltimore, MD, USA. Electronic address:
Objective: Since anti-tumor immunity is enhanced by vaccination of mice adjacent to human papillomavirus type 16 (HPV16+) tumors, we examined whether HPV16 L2E7E6 fusion protein (TA-CIN) vaccination in the thigh of HPV16+ cervical cancer patients would be more immunogenic than their arm.
Methods: HPV16+ cervical cancer (stage IB1-IVA) patients, who had completed standard-of-care treatment within the past year and absent evidence of disease (NED), were enrolled in a pilot study (NCT02405221). Participants were randomized 1:1 to receive three 100 μg TA-CIN monthly intramuscular immunizations either in the arm or thigh and followed for two years for safety (CTCAEv4.
Supporting dialogue amongst multicultural communities: Exploring the role of vaccine champions.
Vaccine
August 2025
School of Population Health, Faculty of Medicine and Health, University of New South Wales, NSW, Australia.
Background: COVID-19 vaccination has significantly reduced the risk of severe disease. Yet, across many settings in Australia, there have been issues with equitable uptake, particularly for some people from ethnic minority backgrounds. To bridge this gap, training workshops were held to support the capacity of local community leaders to communicate about the COVID-19 booster vaccines and other recommended vaccines as local vaccine champions.
View Article and Find Full Text PDFEvaluating Ontario's High Priority Communities Strategy: Integrating Care, Redressing Health Inequities and Improving Population Health "From the Ground Up".
Healthc Q
May 2025
Nasma Ashraf, is a project coordinator at HCSL, Toronto, ON, who applies her experience in health promotion and chronic disease prevention in newcomer and marginalized communities to support innovative, community-led solutions to improve health.
The COVID-19 pandemic revealed profound inequities in the health of Canadians: racially diverse, newcomer and low-income communities were most likely to experience illness and death. In December 2020, Ontario announced the High Priority Communities Strategy (HPCS) that funded "lead agencies" in 17 marginalized communities to support scores of community partners who in turn devised culturally appropriate "micro-strategies" to provide education, tests, vaccinations and wrap-around care. We draw on evaluations conducted over three years to assess the HPCS and synthesize lessons learned for integrating care, reducing health inequities and improving population health from the "ground up.
View Article and Find Full Text PDFRetaining African networks is urgent for global health.
Trends Microbiol
July 2025
SAMRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa; Centre for the AIDS Programme of Research in South Africa, Dur
The Global Immunology and Immune Sequencing for Epidemic Response (GIISER) network, established in 2021, exemplifies the power of South-South collaboration in pandemic preparedness and response. Emerging from the COVID-19 crisis, GIISER integrated genomic surveillance, immunology, and capacity building across African, Asian, and South American sites, enabling rapid detection and characterization of SARS-CoV-2 variants. Through technology transfer, standardized protocols, and coordinated training, GIISER informed public health policy, advanced monoclonal antibody discovery, and strengthened local expertise.
View Article and Find Full Text PDFDrivers of human papillomavirus vaccine uptake in migrant populations and interventions to improve coverage: a systematic review and meta-analysis.
Lancet Public Health
August 2025
The Migrant Health Research Group, Institute for Infection and Immunity, School of Health and Medical Sciences, City St George's, University of London, London, UK. Electronic address:
Background: WHO's Cervical Cancer Elimination Initiative has set a target for 90% of girls to be fully vaccinated against human papillomavirus (HPV) by the age of 15 years by 2030, to substantially reduce deaths from cervical and other HPV-related cancers. However, progress has been slow, with only 27% global vaccine coverage in 2023. Migrants are an under-immunised group globally for many vaccine-preventable diseases, with data showing that they experience a high burden of HPV infection and widespread HPV under-immunisation.
View Article and Find Full Text PDF